Get the Stockscreener App
26.84
1.68%
-0.46
Liquidia Corp stock is traded at $26.84, with a volume of 2.60M.
It is down -1.68% in the last 24 hours and up +61.69% over the past month.
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.
See More
Previous Close:
$27.30
Open:
$27.3
24h Volume:
2.60M
Relative Volume:
0.96
Market Cap:
$2.31B
Revenue:
$17.49M
Net Income/Loss:
$-78.50M
P/E Ratio:
-22.37
EPS:
-1.2
Net Cash Flow:
$-52.85M
1W Performance:
+3.43%
1M Performance:
+61.69%
6M Performance:
+66.55%
1Y Performance:
+178.71%
1-Day Range:
$26.16
$27.69
1-Week Range:
$26.00
$28.00
52-Week Range:
$8.75
$28.00
Liquidia Corp Stock (LQDA) Company Profile
Name
Liquidia Corp
Sector
Industry
Phone
919.328.4400
Address
419 DAVIS DRIVE, SUITE 100, MORRISVILLE, NC
Compare LQDA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LQDA
Liquidia Corp
|
26.84 | 2.39B | 17.49M | -78.50M | -52.85M | -1.20 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Liquidia Corp Stock (LQDA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-15-25 | Resumed | Jefferies | Buy |
| May-19-25 | Downgrade | Oppenheimer | Perform → Underperform |
| Dec-20-24 | Initiated | Wells Fargo | Overweight |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Aug-19-24 | Upgrade | Raymond James | Outperform → Strong Buy |
| Aug-16-24 | Initiated | Raymond James | Outperform |
| Jun-25-24 | Initiated | Oppenheimer | Perform |
| Jan-05-24 | Reiterated | Needham | Buy |
| Sep-19-22 | Resumed | Wedbush | Underperform |
| Sep-01-22 | Downgrade | Wedbush | Neutral → Underperform |
| Jul-22-22 | Initiated | Ladenburg Thalmann | Buy |
| May-31-22 | Initiated | BTIG Research | Buy |
| May-26-22 | Initiated | BofA Securities | Buy |
| Dec-04-20 | Initiated | H.C. Wainwright | Buy |
| Nov-20-20 | Downgrade | Wedbush | Outperform → Neutral |
| Nov-08-18 | Resumed | Jefferies | Buy |
| Sep-05-18 | Initiated | Wedbush | Outperform |
| Aug-20-18 | Initiated | Jefferies | Buy |
| Aug-20-18 | Initiated | Needham | Buy |
View All
Liquidia Corp Stock (LQDA) Latest News
Court Victory and Fresh Funding Propel Growth at Liquidia Corporation - Yahoo Finance
Live Scanner Shows Breakout on Liquidia CorporationPortfolio Gains Summary & Low Risk Entry Point Guides - 한국정경신문
Jefferies initiates Liquidia stock with Buy rating, $43 price target - Investing.com
Jefferies initiates Liquidia stock with Buy rating, $43 price target By Investing.com - Investing.com UK
Pulmonary Hypertension associated with Interstitial Lung Disease Market to Witness Upsurge in Growth During the Forecast Period (2025–2034) | DelveInsight - GlobeNewswire Inc.
Liquidia Technologies stock hits 52-week high at 25.19 USD - Investing.com
Liquidia's Q2 Results Boost Analyst Forecasts, Shares Rise - AInvest
Liquidia's Yutrepia Prescriptions Soar, Shares Rise 13.68% - AInvest
Liquidia (LQDA) Climbs 13.68% as Yutrepia Prescriptions Surge - Insider Monkey
Liquidia stock price target raised to $49 from $40 at BTIG - Investing.com Canada
Liquidia (LQDA) Rating Maintained as Strong Buy by Raymond James - GuruFocus
Wells Fargo Raises Liquidia (LQDA) Price Target to $31 | LQDA St - GuruFocus
Liquidia Corporation (NASDAQ:LQDA) Q2 2025 Earnings Call Transcript - Insider Monkey
Liquidia: Raymond James maintains Strong Buy, raises PT to $41 from $33. - AInvest
Wells Fargo Raises Liquidia PT to $31 from $25, Maintains Overweight Rating - AInvest
Liquidia stock price target raised to $31 by Wells Fargo on strong launch - Investing.com Canada
Liquidia stock price target raised to $41 from $33 at Raymond James - Investing.com Nigeria
Liquidia: Needham Raises PT to $36 from $32, Maintains Buy Rating - AInvest
Liquidia 2025 Q2 Earnings Wider Losses Despite Revenue Surge - AInvest
Liquidia Corp (LQDA) Q2 2025 Earnings Call Highlights: Strong YUTREPIA Launch and Financial Position - Yahoo Finance
Liquidia Corp (LQDA) Q2 2025 Earnings Call Highlights: Strong YU - GuruFocus
Decoding Liquidia Corp (LQDA): A Strategic SWOT Insight - GuruFocus
10 Stocks on Euphoria. Are You Holding Any? - Insider Monkey
United Therapeutics Shares Rise 0.32% Amid Patent Dispute with Liquidia Trading Volume Ranked 420th in Market Activity - AInvest
Liquidia Corporation shares rise 15.19% intraday after reporting positive interim data from ASCENT trial. - AInvest
Liquidia Technologies, Inc. (LQDA) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
Liquidia Stock Surges as Q2 Earnings Beat Expectations - AInvest
Liquidia (LQDA): A High-Growth Biotech Play with Explosive Revenue Momentum and a Path to Profitability - AInvest
Liquidia's Q2 2025 Earnings Call: Unpacking Key Contradictions on YUTREPIA's Market Access and Data Presentation - AInvest
Liquidia Corporation Q2 2025 Earnings Call Transcript Analysis: Key Takeaways and Insights - AInvest
Liquidia Sees Boost in YUTREPIA Adoption, Aims for Expanded Market Access in H2 2025. - AInvest
When Will Liquidia Corporation (NASDAQ:LQDA) Become Profitable? - 富途牛牛
Earnings call transcript: Liquidia Q2 2025 sees revenue surge, stock jumps - Investing.com
Liquidia Q2 2025 slides: Yutrepia launch drives 141% revenue growth amid widening losses - Investing.com
Liquidia Corporation shares surge 13.44% in premarket after strong Q2 earnings and positive drug trial results. - AInvest
Liquidia Stock Soars 10.61% on Q2 Earnings - AInvest
Liquidia Technologies earnings missed by $0.07, revenue topped estimates - Investing.com
Liquidia Corp SEC 10-Q Report - TradingView
Liquidia Corporation Reports Second Quarter 2025 Financial Results and Provides Corporate Update - TradingView
Liquidia Q2 2025 Earnings Preview: Key Estimates and Trends - AInvest
Earnings To Watch: Liquidia Corp (LQDA) Reports Q2 2025 Result - Yahoo Finance
Liquidia (LQDA): Navigating Legal Uncertainty and YUTREPIA's Launch to Unlock Hidden Value - AInvest
Liquidia: Uncertainty Has Always Been A Buying Opportunity (LQDA) - Seeking Alpha
Will Liquidia Corporation Sustain Its Chart BreakoutReversal Alert Based on RSI Indicator Confirmed - beatles.ru
Liquidia Corp expected to post a loss of 43 cents a shareEarnings Preview - TradingView
Liquidia Corporation's Profit Outlook: A Comprehensive Analysis of the Biopharmaceutical Company's Future Prospects - AInvest
Liquidia Corporation's (NASDAQ:LQDA) Profit Outlook - Yahoo Finance
Liquidia Corp Announces Q2 2025 Earnings Release and Webcast - AInvest
Liquidia Technologies Experiences Promising Start with Yutrepia's Strong Launch - AInvest
Liquidia Technologies stock hits 52-week high at 20.33 USD - Investing.com
Liquidia Technologies stock hits 52-week high at 20.33 USD By Investing.com - Investing.com UK
Liquidia Corp Stock (LQDA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):